Trial of Ixazomib for Kaposi Sarcoma

Part of paid clinical trials in San Diego, California.

Sponsor
AIDS Malignancy Consortium
Study ID
NCT04305691
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Kaposi Sarcoma
  • Skin

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ixazomib Citrate — DRUG
    Given PO
  • Quality-of-Life Assessment — OTHER
    Ancillary studies
  • Questionnaire Administration — OTHER
    Ancillary studies

Study Details

This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date
Nov 7, 2023
Status verified
Feb 2026
Primary completion
Mar 15, 2029
Completion
Mar 15, 2029

Study Design

Enrollment
41 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (ixazomib)
    Patients receive ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response may continue treatment for an additional 12 cycles in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Overall response rate [ Time Frame: Up to 4 weeks post treatment ]

Central Contacts

Locations (11)

FacilityCityStateZIPSite coordinators
UC San DiegoSan DiegoCalifornia92093
Jayamalee De Silva
[email protected]
858-822-5377
Erin Reid, MD (PRINCIPAL_INVESTIGATOR)
Zuckerberg San Francisco General HospitalSan FranciscoCalifornia94110
Paul Couey
[email protected]
4155148889
Chia-Ching Wang, MD (PRINCIPAL_INVESTIGATOR)
University of Miami Miller School of MedicineMiamiFlorida33136
Juan C Ramos, MD
[email protected]
305-243-4909
Juan C Ramos, MD (PRINCIPAL_INVESTIGATOR)
University of Illinois Cancer CenterChicagoIllinois60612
Annette Kinsella
[email protected]
312-996-5931
Paul Rubinstein, MD (PRINCIPAL_INVESTIGATOR)
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreMaryland21287
Laura Clark
[email protected]
410-502-5396
Richard Ambinder, MD (PRINCIPAL_INVESTIGATOR)
Washington UniversitySt LouisMissouri63110
Lee Ratner, MD
[email protected]
314-362-5737
Lee Ratner, MD (PRINCIPAL_INVESTIGATOR)
Mount Sinai HospitalNew YorkNew York10029
Daniela Delbeau-Zagelbaum
[email protected]
212-241-2066
Philip Friedlander (PRINCIPAL_INVESTIGATOR)
Abramson Cancer Center at Pennsylvania HospitalPhiladelphiaPennsylvania19106
PAH Research Team
[email protected]
215-829-7089
Daniel Lefler, MD (PRINCIPAL_INVESTIGATOR)
Thomas Street ClinicHoustonTexas77004
Melissa Cariman
[email protected]
713-563-4973
Elizabeth Chiao, MD, MPH (PRINCIPAL_INVESTIGATOR)
Thomas Street ClinicHoustonTexas77004
Melissa Cariman
[email protected]
7135634973
Virginia Mason Medical CenterSeattleWashington98101
Eliza Moore
[email protected]
206-287-6274
David Aboulafia, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Diego, CA

By research site
UC San Diego· San Diego, CAZuckerberg San Francisco General Hospital· San Francisco, CAUniversity of Miami Miller School of Medicine· Miami, FLUniversity of Illinois Cancer Center· Chicago, ILSidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Baltimore, MDWashington University· St Louis, MO

Related Studies